Objective-We aimed to uncover the protein changes of coronary artery in-stent restenosis (ISR) tissue in minipigs with and without streptozotocin-induced diabetes mellitus by quantitative 2-dimensional fluorescence in-gel electrophoresis (2D-DIGE), and to investigate the influences of crucial proteins identified, particularly adipocyte fatty acid binding protein (AFABP), in human arterial smooth muscle cells. Methods and Results-Sirolimus-eluting stents were implanted in the coronary arteries of 15 diabetic and 26 nondiabetic minipigs, and angiography was repeated after 6 months. The intima tissue of significant ISR and non-ISR segments in both diabetic and nondiabetic minipigs was analyzed by 2D-DIGE and MALDI-TOF/TOF mass spectrometry. AFABP level was significantly increased in ISR tissue than in non-ISR tissue in both diabetic and nondiabetic minipigs, with level being higher in diabetic ISR than in nondiabetic ISR tissue. In human arterial smooth muscle cells, overexpression of AFABP significantly altered phenotype and promoted growth and migration, with effects more prominent in highglucose than in low-glucose medium, whereas AFABP knockdown inhibited these effects. AFABP overexpression increased reactive oxygen species production by upregulating the expression of NADPH oxidase subunits Nox1, Nox4, and P22 through multiple pathways, with elevation of downstream gene cyclin D1, matrix metalloproteinase-2, and monocyte chemoattractant protein-1. However, AFABP-induced effects were inhibited by diphenyleneiodonium, pathway inhibitors, and small interfering RNA. In addition, the supernatant from AFABP-expressing human arterial smooth muscle cells and recombinant AFABP also promoted cellular growth and migration. Conclusion-This study has demonstrated that AFABP is significantly increased in coronary artery ISR segments of both diabetic and nondiabetic minipigs. Increased AFABP expression and secretory AFABP of human arterial smooth muscle cells promote growth and migration via reactive oxygen species-mediated activation. (Arterioscler Thromb Vasc Biol. 2013;33:572-580.) Key Words: adipocyte fatty acid binding protein ◼ in-stent restenosis ◼ reactive oxygen species ◼ smooth muscle cells
T he effectiveness of drug-eluting stents in reducing in-stent restenosis (ISR) is more significantly attenuated in patients with diabetes mellitus than in those with no diabetes mellitus, [1] [2] [3] suggesting that the effects of prorestenosis elements may be strengthened in diabetes mellitus, as compared with those in nondiabetes mellitus.
In this study, aiming to clarify the mechanisms of ISR ( Figure  I in the online-only Data Supplement), we implanted sirolimus-eluting stents in major coronary arteries in minipigs with streptozotocin-induced diabetes mellitus (diabetic group, stent number=30) and those with no diabetes mellitus (nondiabetic group, stent number=52). After 6 months, a significant higher ISR ratio was observed by angiography in diabetic (20%) than in nondiabetic group (7.7%). We used quantitative 2-dimensional fluorescence in-gel electrophoresis (2D-DIGE) to dissect the protein changes of ISR intima. In both diabetic and nondiabetic group, a segment with significant ISR and one with no ISR were used for analysis. Among proteins of level alteration, adipocyte fatty acid binding protein (AFABP) was validated to be significantly increased (≥1. 5-fold) in ISR than in non-ISR tissues in both diabetic and nondiabetic groups, with AFABP level being higher in diabetic ISR than in nondiabetic ISR tissue.
AFABP is abundantly expressed in adipose and cardiovascular tissues. 4 Increased serum levels of AFABP are related to vascular inflammation and endothelial dysfunction in patients with atherosclerosis or diabetes mellitus. 5, 6 In cell and animal experiments, AFABP has been shown to modulate inflammatory responses and play a significant role in pathogenesis of atherosclerosis and diabetes mellitus. [7] [8] [9] [10] [11] Based on abovementioned information, we hypothesized that increased AFABP played a role in the formation of ISR in both diabetes mellitus and nondiabetes mellitus, and its effect was augmented in diabetic condition. However, the effects of increased AFABP levels in vascular smooth muscle cells (SMCs) remain unclear.
Here, we have demonstrated that AFABP overexpression induces a profuse production of reactive oxygen species (ROS), and ROS-mediated growth and migration in human aortic smooth muscle cells (hASMCs), and these effects are more significant in high-glucose than in low-glucose medium. AFABP knockdown, in contrast, causes a reduction of ROS and mitigation of these biological effects as compared with controls. The major NADPH oxidase subunits (Nox1, Nox4, and P22) and ROS downstream genes are activated by AFABP overexpression through multiple pathways. Moreover, recombinant and secretory AFABP cause an enhancement of growth and migration in hASMCs. Our results suggest that AFABP is a significant proinflammatory and promigratory factor, which could be an important cause of ISR in both diabetic and nondiabetic condition.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Intracoronary Stenting in Minipigs and Follow-Up
In this study, 15 diabetic minipigs and 26 nondiabetic minipigs were included. The distribution of stents, and angiographic and intravascular ultrasound features at 6 months are detailed in Table I in the online-only Data Supplement. The ISR rate was higher in diabetic group (6 of 30 stents, 20%) than in nondiabetic group (4 of 52 stents, 7.7%), but did not reach a statistical significant level (P>0.05). However, remarkable difference was observed in minimal lumen diameter, late loss, and neointimal volume between diabetic and nondiabetic animals (for all comparison; P<0.05).
AFABP Level Is Significantly Increased in ISR Tissue, as Compared With That in Non-ISR Tissue in Both Diabetic and Nondiabetic Groups
DIGE was used to study the protein profile changes of ISR tissues. In diabetic ISR intima tissue, as shown in Figure  1A , majority of protein spots in gel were increased in levels than in non-ISR intima. Thirty-three spots were found of ≥1.5-fold increase, which were uncovered to be 17 proteins ( Table II in the online-only Data Supplement). In addition, 6 proteins were found of ≥1.5-fold increase in nondiabetic ISR intima ( Figure 1B and Table II in the online-only Data Supplement). Notably, among these increased proteins, AFABP was significantly increased in both diabetic and nondiabetic ISR tissue.
Western blot results validated a significant increase of AFABP protein levels in ISR than in non-ISR intima in both diabetic and nondiabetic groups, with more elevation of AFABP levels in diabetic ISR versus that in nondiabetic ISR tissue (for all comparison, P<0.05; Figure 2A and 2B). We also examined serum AFABP levels in diabetic patients with (18 patients, 26.4±26.6 ng/mL) and without ISR (71 patients, 21.1±14.8 ng/mL), and in nondiabetic patients with (41 patients, 23.1±18.9 ng/mL) and without ISR (138 patients, 20.2±16.8 ng/mL) by ELISA (Biovendor R&D, Modrice, Czech Republic). No statistical significance was observed among their AFABP levels (both P>0.05).
In addition, significant increase of extracellular matrix was observed in ISR slides than in non-ISR slides (staining by Sirius red) in both diabetic and nondiabetic groups, with elevated expression of collagen I and III in ISR tissues ( Figure  II in the online-only Data Supplement).
To investigate the links of AFABP with diabetes mellitus, we treated hASMCs with low-glucose, high-glucose, and advanced glycation end products-bovine serum albumin of increasing doses. High-glucose induces a greater increase of AFABP expression than low-glucose, and addition of advanced glycation end products-bovine serum albumin dose-dependently elicited a further enhancement of AFABP levels on the basis of high-glucose medium (P<0.05; Figure 2C and 2D). In addition, we tested the effects of rapamycin on AFABP expression in hASMCs. Rapamycin unexpectedly induced a dose-dependent increase of AFABP expression in both low-and high-glucose medium, with higher AFABP expression in high-glucose than in low-glucose medium (for all comparison, P<0.05; Figure 2E and 2F).
Overexpression of AFABP Alters Phenotype and Promotes Growth and Migration of hASMCs
To determine the roles of AFABP increment in vascular SMCs, we generated stable hASMCs-expressing vector, AFABP, shRNA-control, and shRNA-AFABP via a retrovirus-mediated method. After selection by G418 and puromycin for 2 weeks, Western blot identified a 5-to 10-fold increase of AFABP expression in AFABP-overexpressing hASMCs and a 60% to 70% reduction of AFABP levels in shRNA-AFABP overexpressing hASMCs, as compared with the levels in untransduced or vector transduced cells ( Figure  3A ). In characterizing these hASMCs, we found that AFABPoverexpression significantly upregulated the expression of collagen I/III, osteopontin, S100A4, interleukin (IL)-1β, and matrix metalloproteinase (MMP)-2/-3/-9 than vector, whereas shRNA-AFABP overexpression downregulated these proteins (for all comparison; P<0.05), indicating enhancement of synthetic, migratory, and inflammatory properties caused by AFABP ( Figure 3B ). Overexpression of AFABP also induced actin polymerization. Compared with vector, hASMCs of AFABP-overexpression showed higher expression and formation of stress fibers when staining these cells with rhodaminephalloidin ( Figure 3C ).
In
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide proliferation assay, hASMCs of AFABP overexpression grew faster than vector transduced cells, whereas AFABP knockdown significantly inhibited cell proliferation ( Figure 3D ; all P<0.05). Wound-healing and Boyden transwell migration assay consistently revealed that AFABP overexpression significantly promoted migration than vector-transduction in hASMCs (P<0.05; Figure 3E -3H). However, AFABP knockdown resulted in decreased migration compared with shRNA-control (P<0.05; Figure  3E -3H). Moreover, the proliferative and migratory effects of AFABP-overexpressing hASMCs were more remarkable in high-glucose than in low-glucose medium (P<0.05; Figure 3D , 3F, and 3H). In both low-glucose and high-glucose cultured cells, these increased proliferation and migration effects of AFABP-overexpression were abrogated by NADPH oxidase inhibitor diphenyleneiodonium.
Overexpression of AFABP Induces an Increase of ROS Production in hASMCs
To investigate whether ROS activation is involved in the mechanisms of AFABP increment, 5-(and-6)-carboxy-2′,7′dichlorodihydrofluorescein diacetate was used to test cellular ROS in stable hASMCs of AFABP, shRNA-AFABP, and vector overexpression and untransduced cells. Notably, overexpression of AFABP induced a more profuse production of O 2 than vector transduction in both low-glucose and high-glucose medium, with O 2 levels of AFABP-overexpressing and vectortransduced hASMCs being more elevated in high-glucose than in low-glucose medium (for all comparison, P<0.05; Figure 4A and 4B). But knockdown of AFABP reduced O 2 generation remarkably than shRNA-control (P<0.05). These results were consistent with a cell-free method to evaluate NADPH oxidase activities in these cells ( Figure 4C ).
AFABP Overexpression Upregulates Nox1, Nox4, and P22 Expression via NF-κB, AP-1, and STAT3
Our experiments showed that AFABP overexpression induced an increase of major NADPH oxidase subunit expression (Nox1, Nox4, and P22) in hASMCs, with high-glucose medium creating an additional enhancement in expression. However, this induction of Nox1, Nox4, and P22 was significantly abrogated by inhibitor pyrrolidine dithiocarbamate, SP600125, or WP1066, indicating that AFABP overexpression elicits promoter activation via NF-κB, AP-1, and STAT3 ( Figure III in the online-only Data Supplement).
Messenger RNA Microarray of hASMCs Transiently Overexpressing AFABP and KEGG Pathway Analysis: Multiple Pathways Are Activated by AFABP Overexpression to Upregulate Nox1, Nox4, and P22
To clarify the signaling pathways provoked by AFABP, we performed mRNA microarray testing in hASMCs transiently overexpressing pLXSN-AFABP, followed by bioinformatic analysis. Compared with control, 362 genes were upregulated and 10 genes were downregulated after AFABP overexpression (Table III in the online-only Data  Supplement) . KEGG pathway analysis uncovered multiple AFABP-induced pathways in hASMCs, such as MAPK, JAK-STAT, chemokine, and Toll-like receptor ( Table IV in the online-only Data Supplement). Western blot results revealed that the levels of phospho-p42/44, phospho-p38, phospho-Akt, MyD88, RalGDS, and p65 were significantly increased in hASMCs of transient AFABP overexpression, whereas AFABP knockdown decreased these protein levels ( Figure IV in the online-only Data Supplement).
We further tested whether inhibition of these pathways affected Nox1, Nox4, and P22 activation. Inhibitors including PD98059, Wortmannin, LY294002, Akt inhibitor IV, MyD88 inhibitor, MyD88 siRNA, and RalGDS siRNA obviously attenuated AFABP-induced Nox1 mRNA levels ( Figure 5A ). Likewise, SB203580, PD98059, Wortmannin, LY294002, Akt inhibitor IV, MyD88 inhibitor, MyD88 siRNA, and RalGDS siRNA decreased mRNA levels of Nox4 and P22 ( Figure 5B and 5C ). In addition, these inhibitors and siRNA almost all inhibited protein levels of Nox1, Nox4, and P22 ( Figure 5D ). 
AFABP Overexpression Increases Expression of Cyclin D1, MMP-2, and MCP-1 via MAPK/PI3K/MyD88/RalGDS-NF-κB/ AP-1/STAT3-ROS Pathways
Secretory and Recombinant AFABP Promote Growth and Migration of hASMCs
Because many adipokines are secretory peptides with paracrine/autocrine effects, we therefore examined AFABP levels in the supernatant from stable hASMCs of AFABP, vector, and shRNA-AFABP overexpression. AFABP protein could be detected in the supernatant of AFABP-overexpressing cells by Western blot (Figure 6A) .
To assess the effects of secretory AFABP, hASMCs were treated by the supernatant from AFABP-and vectoroverexpressing hASMCs with and without anti-AFABP antibody. Compared with vector, the supernatant from AFABP-overexpressing hASMCs significantly promoted cell growth and migration (P<0.05), and these effects were obviously mitigated by anti-AFABP antibody and diphenyleneiodonium (for all comparison, P<0.05; Figure 6B-6F) .
Considering that there were other elements besides AFABP in the supernatant from AFABP-overexpressing hASMCs, which could have biological effects, and to validate secretory AFABP effects, recombinant human AFABP was used to treat hASMCs. Consistent with data of AFABP-containing supernatant, recombinant AFABP dose-dependently promoted growth and migration of hASMCs (for all comparison, P<0.05; Figure  6G -6K), with dose-dependent increase of cyclinD1, MMP-2, and MCP-1 expression in hASMCs ( Figure 6L ).
Because increased macrophage accumulation was related to neointimal formation after arterial injury, 12 we tested whether AFABP-activated macrophages. We found that recombinant AFABP dose-dependently promoted transwell migration in rat peritoneal macrophages, with elevated expression of MMP-2 and MCP-1 ( Figure VI in the online-only Data Supplement).
Discussion
Our study has revealed that AFABP is significantly increased in coronary artery ISR than in non-ISR intimal tissue in both diabetic and nondiabetic minipigs, with AFABP levels being higher in diabetic ISR than in nondiabetic ISR tissue.
In cell experiments, AFABP overexpression promotes ROS production, with enhancement of growth and migration in hASMCs. AFABP effects are more prominent in high-glucose than in low-glucose medium. Moreover, secretory AFABP promotes growth and migration of hASMCs. These discoveries provide novel information regarding ISR mechanisms, as shown in the schematic diagram of our hypothesis ( Figure VII in the online-only Data Supplement).
In line with previous findings of proinflammatory AFABP, 7,8 our study has shown that AFABP increment promotes the growth and migration of vascular SMCs, and the effects are further enhanced when cells are cultured in high-glucose medium. Consistently, we demonstrate that high-glucose and AGE-BSA induce an increase of AFABP expression in hASMCs, indicating that diabetic status could strengthen AFABP effects in vessel wall. In addition, hyperglycemia directly increases ROS production. 13, 14 Thus, diabetic conditions may contribute to augmentation of ROS-mediated mechanisms through pathways including AFABP, which consequently leads to ISR formation.
We have shown that overexpression of AFABP activates pathways, including p38MAPK, p44/42MAPK, JNK, PI3K/ Akt, MyD88/TRAF6, and RalGDS, resulting in upregulation of Nox1, Nox4, and P22. It is known that ERK1/2, p38MAPK-NF-κB; and ERK1/2, p38MAPK-AP-1; or MAPK (ERK1/2, JNK, p38MAPK)-STAT3 pathways mediate inflammatory Overexpression of adipocyte fatty acid binding protein (AFABP) causes reactive oxygen species (ROS) production in human arterial smooth muscle cells (hASMCs). A, Intracellular ROS was examined after incubation with 5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate for 60 minutes. The images were taken immediately. B, After procedure in A, the cells were harvested and dichlorodihydrofluorescein (DCF) fluorescence intensity was detected using a flow cytometer. *P<0.05, vs low-glucose medium; #P<0.01, vs pLXSN-vector in low-glucose medium; &P<0.01, vs pLXSN-vector in high-glucose medium; @P<0.05, vs pLXSN-AFABP in low-glucose and high-glucose medium, respectively; and $P<0.05, vs pLXSNvector. C, NADPH oxidase activities were detected in cells using a cell-free method. *P<0.05, vs low-glucose medium; !P<0.05, vs pLXSN-vector in low-glucose medium; #P<0.001, vs pLXSN-vector in low-glucose medium; &P<0.01, vs pLXSNvector in high-glucose medium; @P<0.01, vs pLXSN-AFABP in low-glucose and high-glucose culture, respectively; and $P<0.05, vs pLXSN-vector. response in vascular SMCs. [15] [16] [17] IL-17A induces cytokine expression via PI3K signaling and TRAF6-dependent NF-κB activation in epithelial cells, and RalGDS transduces growth factor signaling to Akt-mediated signaling cascades besides RalGTPase. 18, 19 Previous studies have also evidenced transcriptional regulation in the promoters of Nox1, Nox4, and P22 by NF-κB, AP-1, and JAK/STAT. [20] [21] [22] Collectively, these reports indicate that activation of pathways, including p38MAPK, ERK1/2, JNK, PI3K/Akt, MyD88/TRAF6, and RalGDS jointly results in activation of NF-κB, AP-1, and STAT, leading to profuse ROS production and downstream gene expression, which are in accordance with our findings.
Rapamycin inhibits cell proliferation and antagonizes inflammation. Interestingly, our study has uncovered an increase of AFABP expression by rapamycin treatment, and this induction is more obvious in high-glucose condition. Previous study has noted similar finding, showing induction of AFABP by rapamycin in human monocytes and macrophages. 23 The mechanism for this remains unclear. In the future, stents with drug coating are desirable to inhibit more 
